title: Recent advances in targeted therapy for glioblastoma.
abstract: Glioblastomas are the most common form of brain tumor with a very dismal prognosis. While a standard treatment regimen of surgery followed by chemo/radiotherapy is currently used, this has only marginally improved the survival time of patients with little benefit on tumor recurrence. Although many molecular targets have already been identified and tested in clinical trials, very few are approved for use in clinics. Efforts are ongoing to target newer molecules that could be used for drug development. This review provides up-to-date information on the drugs and their molecular targets, which are currently in different stages of clinical trials. Since multiple signaling pathways are deregulated, it appears that the use of combination drugs along with personalized targeting approach would provide better therapy in the future.
authors.affiliation: South Campus, Delhi University, Department of Genetics, New Delhi, India.
authors.forename: Shivani
authors.initials: S
authors.lastname: Mittal
authors.forename: Shrikant
authors.initials: S
authors.lastname: Pradhan
authors.forename: Tapasya
authors.initials: T
authors.lastname: Srivastava
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans
chemical_list: D000970:Antineoplastic Agents
keywords: clinical trials; epidermal growth factor receptor; glioblastomas; glioma stem cells; platelet-derived growth factor receptor family; temozolomide; tyrosine kinase inhibitors; vascular endothelial growth factor receptor family